Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized double-blind, double dummy, active comparator-controlled dose finding study in patients with reflux esophagitis Los Angeles grade C or D, and patients with at least partial symptom response but endoscopically still unhealed after 8 weeks history of standard treatment healing course with proton-pump inhibitor (PPI), to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or lansoprazole, and symptom pattern during subsequent 4 weeks treatment with lansoprazole

Next Previous
Trial Profile

A randomized double-blind, double dummy, active comparator-controlled dose finding study in patients with reflux esophagitis Los Angeles grade C or D, and patients with at least partial symptom response but endoscopically still unhealed after 8 weeks history of standard treatment healing course with proton-pump inhibitor (PPI), to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or lansoprazole, and symptom pattern during subsequent 4 weeks treatment with lansoprazole

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linaprazan-glurate (Primary) ; Lansoprazole
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use
  • Acronyms LEED
  • Sponsors Cinclus Pharma

Most Recent Events

  • 17 Oct 2023 Results assessing safety, tolerability, and healing rates after 4 weeks of treatment with LG or lansoprazole presented at the 31st United European Gastroenterology Week
  • 17 Oct 2023 Results assessing efficacy and safety presented at the 31st United European Gastroenterology Week.
  • 16 Oct 2023 According to Cinclus media release, data from this trial are being presented at the leading gastro conference United European Gastroenterology (UEG) which is held in Copenhagen 14 - 17 October 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top